Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues

January 8, 2024

https://www.globenewswire.com/news-release/2024/01/08/2805508/0/en/Apellis-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2023-U-S-Net-Product-Revenues.html

WALTHAM, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq:APLS) today announced preliminary U.S. net product revenues of approximately $138 million for the fourth quarter and approximately $366 million for the full year 2023 for SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration and for EMPAVELI® (pegcetacoplan) for adults with paroxysmal nocturnal hemoglobinuria (PNH).

Read more at globenewswire.com

Related news for (APLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.